Search
plecanatide (Trulance)
Indications:
- adults with chronic idiopathic constipation
Dosage:
- 3 mg PO QD (swallow tablets whole)
Contraindications:
- persons < 18 years of age (children & adolecents)
Mechanism of action:
- guanylate cyclase-C agonist
- stimulates secretion of intestinal fluid
General
polypeptide
gastrointestinal agent
Database Correlations
PUBCHEM cid=70693500
References
- FDA News Release. Jan 19, 2017
FDA approves Trulance for Chronic Idiopathic Constipation.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm537725.htm
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P.
Randomized clinical trial: efficacy and safety of plecanatide
in the treatment of chronic idiopathic constipation.
Therap Adv Gastroenterol. 2017 Nov;10(11):837-851. Epub 2017 Oct 25.
PMID: 29147135 Free PMC Article
- TRULANCE (plecanatide) prescribing information
http://content.stockpr.com/synergypharma/files/pages/synergypharma/db/147/description/03+Plecanatide+label_clean_2017-01-19.pdf